title: [The influence of citoflavin on molecular mechanisms of hypertensive encephalopathy development in patients with systolic arterial hypertension].
abstract: The molecular pharmacological effects of cytoflavin in patients with hypertensive encephalopathy (HE) and isolated systolic arterial hypertension (ISAH) have been investigated using the following methods: assessment of complaints, 24-hour arterial pressure monitoring, ultrasound diagnostics including echocardiography, measurement of lipid profiles and coagulograms, and molecular phenotyping by MALDI-TOF/TOF-MS. A combination of cytoflavin administration with standard therapy of HE and ISAH led to the most expressed return development of clinical symptoms, restoration of the hemodynamic, structural, and geometrical parameters of cardiovascular system, and normalization of the indices of lipid profiles and coagulograms in comparison to patients with HE and ISAH, which accepted only standard therapy. Molecular mechanisms of cytoflavin action have been revealed, which include control of the activity of cellular signaling pathways by means of intermolecular interactions. The optimized therapy of HE and ISAH is recommended for clinical application, which assumes a combined use of standard therapy and cytoflavin and provides a geroprotective action upon the cardiovascular system.
authors.forename: E A
authors.initials: EA
authors.lastname: Kartashova
authors.forename: M G
authors.initials: MG
authors.lastname: Romantsov
authors.forename: I V
authors.initials: IV
authors.lastname: Sarvilina
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D017311:Amlodipine / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D000069059:Atorvastatin; D001794:Blood Pressure / Q000187:drug effects; D001798:Blood Proteins / Q000378:metabolism; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D004452:Echocardiography; D005260:Female; D005486:Flavin Mononucleotide / Q000627:therapeutic use*; D006439:Hemodynamics / Q000187:drug effects; D006538:Heptanoic Acids / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D020343:Hypertensive Encephalopathy / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D007290:Inosine Diphosphate / Q000627:therapeutic use*; D008297:Male; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D009536:Niacinamide / Q000627:therapeutic use*; D011758:Pyrroles / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D013386:Succinates / Q000627:therapeutic use*; D013599:Systole; D013777:Tetrazoles / Q000627:therapeutic use; D014633:Valine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000068756:Valsartan
chemical_list: D001798:Blood Proteins; D004338:Drug Combinations; D006538:Heptanoic Acids; D018696:Neuroprotective Agents; D011758:Pyrroles; D013386:Succinates; D013777:Tetrazoles; C507879:cytoflavin; D017311:Amlodipine; D009536:Niacinamide; D005486:Flavin Mononucleotide; D000068756:Valsartan; D007290:Inosine Diphosphate; D000069059:Atorvastatin; D014633:Valine; D001241:Aspirin